<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	
	>
<channel>
	<title>
	Comments on: New RE-VERSE AD™ analyses provide additional insights on impact of Praxbind® (idarucizumab) in Pradaxa® (dabigatran etexilate) patients with gastrointestinal bleeding or needing emergency surgery	</title>
	<atom:link href="https://www.novumpr.nl/2017/11/14/new-re-verse-ad-analyses-provide-additional-insights-on-impact-of-praxbind-idarucizumab-in-pradaxa-dabigatran-etexilate-patients-with-gastrointestinal-bleeding-or-needing-emer/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.novumpr.nl/2017/11/14/new-re-verse-ad-analyses-provide-additional-insights-on-impact-of-praxbind-idarucizumab-in-pradaxa-dabigatran-etexilate-patients-with-gastrointestinal-bleeding-or-needing-emer/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=new-re-verse-ad-analyses-provide-additional-insights-on-impact-of-praxbind-idarucizumab-in-pradaxa-dabigatran-etexilate-patients-with-gastrointestinal-bleeding-or-needing-emer</link>
	<description>NovumPR press releases</description>
	<lastBuildDate>Tue, 14 Nov 2017 12:30:44 +0000</lastBuildDate>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.8.2</generator>
</channel>
</rss>
